Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Vactosertib in Colorectal Cancer With Resectable Hepatic Metastases
NCT03844750Phase 2Terminated
- Sponsor
- Chloe Atreya
- Start
- Jul 2019
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and vactosertib in colorectal cancer (CRC), sponsored by Chloe Atreya. Primary endpoint: Proportion of Patients With a >= 2-fold Increase in the Tumor-infiltrating Cells Per Unit Area (5 High Power Fields) in Post- Versus Pre Pembrolizumab Treatment Tumor Specimens up to 2 years. Started Jul 2019; status: terminated.
02
Drugs
pembrolizumabvactosertib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03844750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03844750.